CoChat

Hepatocyte growth factor prevents lupus nephritis in a murine lupus model of chronic graft-versus-host disease

Open access

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

Chronic graft-versus-host disease (GVHD) induced in (C57BL/6 × DBA/2) F1 (BDF1) mice by the injection of DBA/2 mouse spleen cells represents histopathological changes associated with systemic lupus erythematosus (SLE), primary biliary cirrhosis (PBC) and Sjogren's syndrome (SS), as indicated by glomerulonephritis, lymphocyte infiltration into the periportal area of the liver and salivary glands. We determined the therapeutic effect of hepatocyte growth factor (HGF) gene transfection on lupus using this chronic GVHD model. Chronic GVHD mice were injected in the gluteal muscle with either HVJ liposomes containing 8 μg of the human HGF expression vector (HGF-HVJ liposomes) or mock vector (untreated control). Gene transfer was repeated at 2-week intervals during 12 weeks. HGF gene transfection effectively prevented the proteinuria and histopathological changes associated with glomerulonephritis. While liver and salivary gland sections from untreated GVHD mice showed prominent PBC- and SS-like changes, HGF gene transfection reduced these histopathological changes. HGF gene transfection greatly reduced the number of splenic B cells, host B cell major histocompatibility complex class II expression, and serum levels of IgG and anti-DNA antibodies. IL-4 mRNA expression in the spleen, liver, and kidneys was significantly decreased by HGF gene transfection. CD28 expression on DBA/2 CD4+ T cells was decreased by the addition of recombinant HGF in vitro. Furthermore, IL-4 production by DBA/2 CD4+ T cells stimulated by irradiated BDF1 dendritic cells was significantly inhibited by the addition of recombinant HGF in vitro. These results suggest that HGF gene transfection inhibited T helper 2 immune responses and reduced lupus nephritis, autoimmune sialoadenitis, and cholangitis in chronic GVHD mice. HGF may represent a novel strategy for the treatment of SLE, SS and PBC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/ar2012

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Therapeutic effects of hepatocyte growth factor (HGF) on the progression of lupus nephritis. (a) Protective effect of HGF against the development of nephritic syndrome, as determined by changes in urine protein excretion levels. Open circles, HGF-treated graft-versus-host disease (GVHD; n = 10); closed circles, untreated GVHD (n = 10). Data represent mean ± standard error (n = 10). *p < 0.05; **p < 0.01 compared to untreated GVHD at the same time point. (b) Histopathology of kidney tissue from untreated and HGF-treated GVHD mice. Mononuclear cell infiltration into the perivascular area of the kidney was observed at 3 weeks, and glomerulonephritis, as shown by glomerular enlargement, increased glomerular lobularity, mesangial hypercellularity, and membrane thickening was observed at 12 weeks after GVHD induction. HGF treatment significantly inhibited these pathological changes. Original magnification ×200.
Figure 1 Therapeutic effects of hepatocyte growth factor (HGF) on the progression of lupus nephritis. (a) Protective effect of HGF against the development of nephritic syndrome, as determined by changes in urine protein excretion levels. Open circles, HGF-treated graft-versus-host disease (GVHD; n = 10); closed circles, untreated GVHD (n = 10). Data represent mean ± standard error (n = 10). *p < 0.05; **p < 0.01 compared to untreated GVHD at the same time point. (b) Histopathology of kidney tissue from untreated and HGF-treated GVHD mice. Mononuclear cell infiltration into the perivascular area of the kidney was observed at 3 weeks, and glomerulonephritis, as shown by glomerular enlargement, increased glomerular lobularity, mesangial hypercellularity, and membrane thickening was observed at 12 weeks after GVHD induction. HGF treatment significantly inhibited these pathological changes. Original magnification ×200.CC BY · PubMed Central
Figure 2 Inhibitory effect of hepatocyte growth factor (HGF) on mononuclear infiltration in the liver and the salivary glands. Chronic graft-versus-host disease (GVHD) mice were treated as described in Figure 1, and histopathology of the liver and salivary glands examined 12 weeks after GVHD induction. HGF treatment inhibited mononuclear cell infiltration into the liver and salivary glands of chronic GVHD mice. Original magnification ×200.
Figure 2 Inhibitory effect of hepatocyte growth factor (HGF) on mononuclear infiltration in the liver and the salivary glands. Chronic graft-versus-host disease (GVHD) mice were treated as described in Figure 1, and histopathology of the liver and salivary glands examined 12 weeks after GVHD induction. HGF treatment inhibited mononuclear cell infiltration into the liver and salivary glands of chronic GVHD mice. Original magnification ×200.CC BY · PubMed Central
Figure 3 Effect of hepatocyte growth factor (HGF) on host B cell activation and donor anti-host cytotoxic T lymphocyte (CTL) activity. Chronic graft-versus-host disease (GVHD) mice were treated as described in Figure 1. (a) At 2 weeks after GVHD induction, spleens were removed and H-2Kb+B220+ cells examined by flow cytometry. Data represent mean ± SD for four mice per group. (b) At 2 weeks after GVHD induction, serum IgG1 concentrations were determined by ELISA. Data represent mean ± SD for four mice per group. (c) At 2 weeks after GVHD induction, serum anti-single-stranded DNA antibody concentrations were determined by ELISA. Data represent mean ± SD for four mice per group. (d) At 2 weeks after GVHD induction, spleen cells were stimulated with irradiated BDF1 spleen cells for 5 days. Cytotoxicity was determined by CTL activity against 51Cr-labeled EL-4 (H-2b) target cells. CTL activity against P815 cells (H-2d) by acute GVHD mouse spleen cells was used as a positive control. Effector cells were tested in triplicate at four effector:target (E/T) ratios and the percent lysis calculated. Data represent mean ± SD for four mice per group.
Figure 3 Effect of hepatocyte growth factor (HGF) on host B cell activation and donor anti-host cytotoxic T lymphocyte (CTL) activity. Chronic graft-versus-host disease (GVHD) mice were treated as described in Figure 1. (a) At 2 weeks after GVHD induction, spleens were removed and H-2Kb+B220+ cells examined by flow cytometry. Data represent mean ± SD for four mice per group. (b) At 2 weeks after GVHD induction, serum IgG1 concentrations were determined by ELISA. Data represent mean ± SD for four mice per group. (c) At 2 weeks after GVHD induction, serum anti-single-stranded DNA antibody concentrations were determined by ELISA. Data represent mean ± SD for four mice per group. (d) At 2 weeks after GVHD induction, spleen cells were stimulated with irradiated BDF1 spleen cells for 5 days. Cytotoxicity was determined by CTL activity against 51Cr-labeled EL-4 (H-2b) target cells. CTL activity against P815 cells (H-2d) by acute GVHD mouse spleen cells was used as a positive control. Effector cells were tested in triplicate at four effector:target (E/T) ratios and the percent lysis calculated. Data represent mean ± SD for four mice per group.CC BY · PubMed Central
Figure 4 Effect of hepatocyte growth factor (HGF) on cytokine gene expression by chronic graft-versus-host disease (GVHD) mice. Chronic GVHD mice were treated as described in Figure 1. At 2 weeks after GVHD induction, spleen, liver, and kidneys were removed and IFN-γ and IL-4 mRNA expression determined by RT-PCR analysis. Data represent mean ± SD for four mice per group. *p < 0.05 compared to untreated GVHD.
Figure 4 Effect of hepatocyte growth factor (HGF) on cytokine gene expression by chronic graft-versus-host disease (GVHD) mice. Chronic GVHD mice were treated as described in Figure 1. At 2 weeks after GVHD induction, spleen, liver, and kidneys were removed and IFN-γ and IL-4 mRNA expression determined by RT-PCR analysis. Data represent mean ± SD for four mice per group. *p < 0.05 compared to untreated GVHD.CC BY · PubMed Central
Figure 5 Effect of hepatocyte growth factor (HGF) on B cell MHC class II expression. (a) Chronic graft-versus-host disease (GVHD) mice were treated as described in Figure 1. At 2 weeks after GVHD induction, spleens were removed and the mean fluorescence intensity of MHC class II (I-Ab) expression on B220+ cells determined. Data represent mean ± SD for four mice per group. *p < 0.05. (b) B220+ cells from BDF1 mice (2 × 106/ml) were cultured with mouse recombinant IL-4 (10 ng/ml) in the presence or absence of human recombinant HGF (10 ng/ml) for 48 h, and mean fluorescence intensity of MHC class II (I-Ab) expression on B220+ cells determined. Data represent mean ± SD of three independent experiments. *p < 0.05. (c) CD4+ T cells from DBA/2 (H-2d) mice (4 × 106/ml/well) were cultured with irradiated (20 Gy) CD11c+ dendritic cell (DCs) from BDF1 (H-2b×d) mice (1 × 106/ml/well) in the presence or absence of human recombinant HGF (10 ng/ml). After 72 h, viable cells (1 × 106/ml) were cultured with B220+ cells from BDF1 mice (2 × 106/ml) for 48 h and mean fluorescence intensity of MHC class II (I-Ab) expression on B220+ cells determined. Data represent mean ± SD of three independent experiments. *p < 0.05.
Figure 5 Effect of hepatocyte growth factor (HGF) on B cell MHC class II expression. (a) Chronic graft-versus-host disease (GVHD) mice were treated as described in Figure 1. At 2 weeks after GVHD induction, spleens were removed and the mean fluorescence intensity of MHC class II (I-Ab) expression on B220+ cells determined. Data represent mean ± SD for four mice per group. *p < 0.05. (b) B220+ cells from BDF1 mice (2 × 106/ml) were cultured with mouse recombinant IL-4 (10 ng/ml) in the presence or absence of human recombinant HGF (10 ng/ml) for 48 h, and mean fluorescence intensity of MHC class II (I-Ab) expression on B220+ cells determined. Data represent mean ± SD of three independent experiments. *p < 0.05. (c) CD4+ T cells from DBA/2 (H-2d) mice (4 × 106/ml/well) were cultured with irradiated (20 Gy) CD11c+ dendritic cell (DCs) from BDF1 (H-2b×d) mice (1 × 106/ml/well) in the presence or absence of human recombinant HGF (10 ng/ml). After 72 h, viable cells (1 × 106/ml) were cultured with B220+ cells from BDF1 mice (2 × 106/ml) for 48 h and mean fluorescence intensity of MHC class II (I-Ab) expression on B220+ cells determined. Data represent mean ± SD of three independent experiments. *p < 0.05.CC BY · PubMed Central
Figure 6 In vitro effect of hepatocyte growth factor (HGF) on T helper (Th)2 generation from DBA/2 CD4+ T cells. CD4+ T cells from DBA/2 (H-2d) mice (4 × 106/ml/well) were cultured with irradiated (20 Gy) CD11c+ dendritic cell (DCs) from BDF1 (H-2b×d) mice (1 × 106/ml/well) in the presence or absence of human recombinant HGF (10 ng/ml). CD4+ T cells from DBA/2 (H-2d) mice (4 × 106/ml/well) cultured without CD11c+ DC stimulation were used as controls. After 72 h, viable cells (1 × 105/200 μl/well) were harvested and stimulated with anti-CD3 mAb (5 μg/ml) for 48 h. The concentration of IL-4 (a) and IFN-γ (b) in the culture supernatant was measured by ELISA. Data represent mean ± SD of three independent experiments. *p < 0.05; **p < 0.01.
Figure 6 In vitro effect of hepatocyte growth factor (HGF) on T helper (Th)2 generation from DBA/2 CD4+ T cells. CD4+ T cells from DBA/2 (H-2d) mice (4 × 106/ml/well) were cultured with irradiated (20 Gy) CD11c+ dendritic cell (DCs) from BDF1 (H-2b×d) mice (1 × 106/ml/well) in the presence or absence of human recombinant HGF (10 ng/ml). CD4+ T cells from DBA/2 (H-2d) mice (4 × 106/ml/well) cultured without CD11c+ DC stimulation were used as controls. After 72 h, viable cells (1 × 105/200 μl/well) were harvested and stimulated with anti-CD3 mAb (5 μg/ml) for 48 h. The concentration of IL-4 (a) and IFN-γ (b) in the culture supernatant was measured by ELISA. Data represent mean ± SD of three independent experiments. *p < 0.05; **p < 0.01.CC BY · PubMed Central
Figure 7 Effect of hepatocyte growth factor (HGF) on CD4+ T cell CD28 expression and on CD11c+ dendritic cell (DC) CD86 expression. (a) CD4+ T cells from DBA/2 (H-2d) or B6 (H-2b) mice (4 × 106/ml/well) were cultured in the presence or absence of human recombinant HGF (10 ng/ml). After 48 h, mean fluorescence intensity of CD28 expression on CD4+ T cells determined. Data represent mean ± SD of three independent experiments. *p < 0.05. (b,c) CD4+ T cells from DBA/2 (H-2d) or B6 (H-2b) mice (4 × 106/ml/well) were cultured with irradiated (20 Gy) CD11c+ DCs from BDF1 (H-2b×d) mice (1 × 106/ml/well) in the presence or absence of human recombinant HGF (10 ng/ml) for 48 h, and mean fluorescence intensity of CD28 expression on CD4+ T cells (b) and CD86 expression on CD11c+ DCs (c) determined. Data represent mean ± SD of three independent experiments. *p < 0.05; **p < 0.01.
Figure 7 Effect of hepatocyte growth factor (HGF) on CD4+ T cell CD28 expression and on CD11c+ dendritic cell (DC) CD86 expression. (a) CD4+ T cells from DBA/2 (H-2d) or B6 (H-2b) mice (4 × 106/ml/well) were cultured in the presence or absence of human recombinant HGF (10 ng/ml). After 48 h, mean fluorescence intensity of CD28 expression on CD4+ T cells determined. Data represent mean ± SD of three independent experiments. *p < 0.05. (b,c) CD4+ T cells from DBA/2 (H-2d) or B6 (H-2b) mice (4 × 106/ml/well) were cultured with irradiated (20 Gy) CD11c+ DCs from BDF1 (H-2b×d) mice (1 × 106/ml/well) in the presence or absence of human recombinant HGF (10 ng/ml) for 48 h, and mean fluorescence intensity of CD28 expression on CD4+ T cells (b) and CD86 expression on CD11c+ DCs (c) determined. Data represent mean ± SD of three independent experiments. *p < 0.05; **p < 0.01.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Research works printed but not linked: 1

  1. Rus V Svetic A Nguyen P Gause WC Via CS Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. Regulatory role of donor CD8+ T cells J Immunol 1995 155 2396 2406 7650373 · DOI · Paper page

Cited by

See all 44

Metadata

Authors
Kuroiwa, T., Iwasaki, T., Imado, T., Sekiguchi, M., Fujimoto, J., & Sano, H.
Affiliations
Hyogo Medical University (JP)
Corresponding author
Iwasaki, Tsuyoshi
Venue
Arthritis Research & Therapy
Published
2006-07-19
Volume
8
Issue
4
Pages
R123-R123
ISSN
1478-6354 (ISSN-L)
OpenAlex
W2120665673
Cited by
39
References
33
Citations by year
2026: 1 · 2024: 1 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 1 · 2018: 2 · 2016: 1 · 2015: 5 · 2014: 4 · 2013: 3 · 2012: 2
FWCI
1.97
Type
journal article
Language
en
Open access
Licence
Locations
  • Arthritis Research & Therapy (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
  • Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
  • Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
Keywords
hepatocyte growth factor, lupus nephritis, chronic graft-versus-host disease, systemic lupus erythematosus, primary biliary cirrhosis, Sjögren's syndrome, transfection, HVJ-liposome, glomerulonephritis, proteinuria, sialadenitis, cholangitis, IL-4, T helper 2 response, CD28, anti-DNA antibodies, autoimmunity
MeSH terms
Animals, Histocompatibility Antigens Class II, Antibodies, Antinuclear, B-Lymphocytes, Cell Differentiation, Chronic Disease, Disease Models, Animal, DNA, Female, Graft vs Host Disease, Humans, Immunoglobulin G, Liver Cirrhosis, Biliary, Lupus Nephritis, Mice, Inbred Strains, Osmolar Concentration, Proteinuria, RNA, Messenger, Sjogren's Syndrome, Spleen, Transfection, CD4-Positive T-Lymphocytes, Down-Regulation, Interleukin-4, Hepatocyte Growth Factor, CD28 Antigens, Th2 Cells, Lymphocyte Count, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.